工商银行 1-9 月归母净利润、营业收入、PPOP 分别同比+0.3%、+2.2%、 +2.0%，增速较 1-6 月+1.7pct、+0.6pct、+0.4pct。 公司业绩边际改善，非 息收入增速回升，中收增速由负转正，资产质量稳健。我们认为龙头地位稳 固，A/H 股维持买入/买入评级。 证券研究报告 工商银行 (601398 CH/1398 HK) 港股通 非息增速改善助力业绩回稳 华泰研究 季报点评 2025 年 10 月 31 日│中国内地/中国香港 国有大型银行 聚焦支持"四稳"，服务实体提质扩面。公司靠前对接各项存量和增量政策， 承销首批股权投资机构科技创新债券，AIC 股权投资试点业务规模行业领 先。突出"工"的主责主业和"商"的专业特色，做好金融"五篇大文章"，加力支 持国民经济重大战略、重点领域和薄弱环节，制造业、科技创新、绿色发展、 普惠小微等领域贷款增速均高于各项平均；积极支持提振消费、保障民生， 加强消费者权益保护，6 月末个人消费贷款增长 10.2%。 给予 A/H 股 26 年目标 PB0.85/0.65 倍 规模持续增长，息差略有波动 9 月末总资产、贷款、存款增速分别为+9.2 ...

Investment Rating - The report maintains a "Buy" rating for both A and H shares of the company [8] Core Views - The company has shown significant growth in revenue and net profit for Q3 2025, with revenue reaching 10.766 billion RMB (up 51.82% YoY, 31.97% QoQ) and net profit at 4.465 billion RMB (up 85.86% YoY, 20.26% QoQ) [1][2] - The company is planning to issue H shares, with a general authorization to issue up to 20% of the already issued H shares, which could enhance its capital strength and profitability [5][6] Financial Performance - Total assets reached 953.4 billion RMB by the end of Q3 2025, a 26% increase from the beginning of the year and a 17% increase quarter-on-quarter [2] - The leverage ratio increased to 4.76x, up 0.81x year-to-date and 0.63x quarter-on-quarter, indicating rapid leverage growth [2] - The company achieved a net profit of 10.934 billion RMB for the first three quarters of 2025, a 62% increase YoY [2] Business Segments - Investment and brokerage revenues grew significantly, with investment income up 57% and brokerage income up 75% YoY, contributing 36% and 27% to total revenue, respectively [2][4] - The financial investment scale increased by 16% quarter-on-quarter to 482 billion RMB, with trading financial assets rising by 22% [3] - The brokerage business net income for Q3 2025 was 3.1 billion RMB, a 149% increase YoY, driven by a rise in A-share trading volume [4] Profit Forecast and Valuation - The report projects net profits for 2025-2027 to be 14.371 billion, 16.545 billion, and 19.108 billion RMB, respectively, with corresponding EPS of 1.89, 2.18, and 2.51 RMB [6][12] - The target prices are set at 30.95 RMB for A shares and 27.15 HKD for H shares, reflecting a PB valuation of 1.5 for A shares and 1.2 for H shares [6][8]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company achieved Q3 revenue of 4.567 billion RMB, representing a year-over-year increase of 25.54% and a quarter-over-quarter increase of 4.65%. The net profit attributable to shareholders was 506 million RMB, up 18.95% year-over-year but down 8.58% quarter-over-quarter. For the first three quarters of 2025, the company reported a total revenue of 12.914 billion RMB, a year-over-year increase of 18.82%, and a net profit of 1.470 billion RMB, up 15.78% year-over-year [1][7] - The growth in revenue is primarily attributed to the sustained demand in the relay sector and the acceleration of new product categories, with expectations for continued performance growth driven by overseas markets and data centers [1][3] Summary by Sections Financial Performance - In Q3 2025, the gross margin was 35.35%, showing a quarter-over-quarter increase of 0.69 percentage points despite rising raw material costs and competitive pricing pressures. The net profit margin was 14.63%, down 1.03 percentage points year-over-year and 2.20 percentage points quarter-over-quarter, mainly due to an increase in the expense ratio [2] - The company generated a net cash flow from operating activities of 1.573 billion RMB in the first three quarters of 2025, reflecting a year-over-year increase of 30.49% [2] Product Development and Market Position - The company is strengthening its core business in relays while actively expanding into new product categories such as fuses and film capacitors. A five-year plan has been established to guide the achievement of phased goals and drive order and revenue growth [3] - The company is also developing modular solutions, such as high-voltage control boxes, to enhance product value and increase the self-manufacturing ratio of new product categories [3] Growth Opportunities - The company has a rich reserve of components and solutions for data centers, including relays, connectors, and various power distribution solutions. The shift from AC to DC power supply architectures in AI data centers is expected to enhance demand for the company's products, providing new growth momentum [4] Profit Forecast and Valuation - The company’s net profit forecasts for 2025-2027 have been adjusted upward by 1.30%, 2.10%, and 3.92% to 1.893 billion RMB, 2.195 billion RMB, and 2.590 billion RMB, respectively, with a three-year compound growth rate of 16.66%. The target price is set at 44.68 RMB, based on a PE ratio of 29.71 for 2026 [5]

Investment Rating - The report assigns an investment rating of "Buy (First Coverage)" with a current price of 64.70 CNY and a target price of 101.82 CNY over a 12-month period [1][5]. Core Insights - The report highlights that the IDE (Integrated Development Environment) business is expected to be the core growth driver for the company, with significant revenue growth projected from 2025 to 2027 [5][33]. - The company is strategically positioned in the AI and programming sector, leveraging AI technologies to enhance its IDE offerings [5][27]. - The global software development tools market is projected to grow from 6.517 billion USD in 2025 to 14.680 billion USD by 2031, with a CAGR of 14.5% [5][28]. Company Overview - The report details that Jiangsu Zhaoyi Information Technology Co., Ltd. was established in May 2008 and went public on the Shanghai Stock Exchange in December 2019 [13][19]. - The company’s main business segments include IDE business, core firmware for cloud computing devices, and cloud services [13][33]. Financial Performance - The company’s revenue is projected to grow from 414.33 million CNY in 2025 to 827.17 million CNY in 2027, with corresponding net profits expected to rise from 93.87 million CNY to 289.99 million CNY during the same period [6][5]. - The report provides a detailed financial forecast, indicating a significant increase in both revenue and net profit over the next three years [6][5]. Business Analysis - The IDE business is identified as a key area for future growth, with products like SnapDevelop and EazyDevelop being central to the company's strategy [5][36]. - The company has a dual strategy of "IDE+AI" and "AI+IDE," focusing on enhancing development efficiency through AI integration [5][36]. - The report notes that the company has a strong management team with a stable background, which is crucial for executing its growth strategy [5][23]. Industry Analysis - The IDE industry is undergoing significant transformation due to advancements in AI, cloud computing, and low-code technologies, which are expected to drive future growth [27][31]. - The report emphasizes the scarcity of domestic companies with mature IDE development capabilities, positioning the company as a rare player in the market [27][28].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [8][10]. Core Insights - The company has demonstrated rapid revenue growth, with a 47.4% year-over-year increase in revenue for the first three quarters of 2025, reaching 410 million RMB. The net profit for the same period increased by 59.2% to 90 million RMB [9][11]. - The growth is attributed to the recovery in the downstream robotics market and the completion of a production expansion project, which has increased the company's capacity [11]. - The company is actively expanding into new fields such as embodied intelligence and machine tools, which are expected to drive future growth [11]. Summary by Sections Company Overview - The company operates in the machinery equipment industry, with a current stock price of 159.92 RMB and a market capitalization of 29.318 billion RMB [2]. Recent Ratings - The company has consistently received "Buy" ratings in recent reports, with the latest rating issued on December 4, 2024 [3]. Product Portfolio - The product mix includes 78.3% harmonic reducers and metal components, 16.6% mechatronic products, and 3.2% intelligent automation equipment [4]. Financial Performance - For Q3 2025, the company reported a gross margin of 39.6%, an increase of 1.5 percentage points year-over-year, and a net profit margin of 25.9%, up 4.5 percentage points [11]. - The company expects net profits of 120 million RMB, 150 million RMB, and 203 million RMB for 2025, 2026, and 2027, respectively, reflecting significant growth [11][13]. Market Position - The company is a leader in the harmonic reducer market and is well-positioned to benefit from the growth in industrial robotics production, which increased by 29.8% year-over-year [11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 1.94 CNY based on a price-to-book (PB) ratio of 1.08X for comparable companies in 2025 [3][5]. Core Insights - The company is expected to enhance its profitability through quality asset injections and cost reduction initiatives, with a significant improvement in operational efficiency and product structure optimization [2][10]. - The company reported a net profit of approximately 140 million CNY for the first three quarters of 2025, marking a turnaround from losses, with a substantial quarter-on-quarter growth of 372.45% in Q3 2025 [10]. - The acquisition of 100% equity in Yingshan Steel is projected to increase crude steel production capacity by 5.6 million tons, enhancing overall production efficiency and product mix [10]. - Continuous efforts in cost control have led to a reduction of 64.39 CNY per ton of steel in comparable costs, alongside a 16.1% optimization rate in on-site staff at the Jinan Steel City base [10]. Financial Performance Summary - Revenue is projected to decline from 90.475 billion CNY in 2023 to 77.780 billion CNY in 2025, with a year-on-year decrease of 11.5% in 2023 and 5.3% in 2025 [13]. - The company is expected to achieve a net profit of 250 million CNY in 2025, recovering from a loss of 400 million CNY in 2023 [13]. - The gross margin is anticipated to improve from 4.0% in 2023 to 5.6% in 2025, with net profit margin turning positive at 0.3% in 2025 [13]. - The return on equity (ROE) is projected to recover from -1.9% in 2023 to 1.3% in 2025, indicating a positive trend in profitability [13].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1][6] Core Insights - The company reported a revenue of 2.327 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 2%. The net profit attributable to the parent company was 80 million yuan, marking a return to profitability [3][6] - The company is experiencing improvements in profitability, with a gross margin of 30.59% in Q3 2025, an increase of 2.54 percentage points year-on-year. The net profit margin for Q3 2025 was -1.33%, which is an improvement of 5.19 percentage points year-on-year [6] - The company is focusing on expanding its overseas market presence and has made significant progress in its automotive business, with several models already equipped with its projection products [6] Financial Data and Profit Forecast - Total revenue projections for 2025E are 3.868 billion yuan, with a year-on-year growth rate of 13.6%. The net profit forecast for 2025E is 293 million yuan, representing a year-on-year increase of 144.2% [5][6] - The company has adjusted its profit forecasts for 2025-2027, now expecting net profits of 293 million yuan, 386 million yuan, and 472 million yuan respectively, with corresponding P/E ratios of 25, 19, and 15 [6][5] - The company’s R&D expenses have increased, impacting short-term profitability but are expected to drive long-term growth in revenue and profits from its automotive and commercial projection businesses [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in Q1-Q3 2025 was below market expectations, with revenue of 6.79 billion yuan, a year-on-year increase of 15.05%, and a net profit attributable to shareholders of 210 million yuan, a year-on-year decrease of 48.29% [7] - The company is significantly investing in AI power business, participating in the design and construction of data center hardware systems based on NVIDIA's Blackwell architecture, and has launched several new products [7] - The company is facing challenges in its home appliance business due to weak downstream demand and increased competition, while the new energy vehicle business continues to grow [7] Summary by Sections Financial Performance - Total revenue for 2023 is projected at 6.754 billion yuan, with a year-on-year growth of 23.30% [1] - Net profit attributable to shareholders for 2023 is expected to be 629.32 million yuan, reflecting a year-on-year increase of 33.13% [1] - The gross margin for Q1-Q3 2025 was 21.8%, a decrease of 3.83 percentage points year-on-year [7] Business Segments - Home Appliance Business: The company is adjusting its pricing strategy due to decreased overseas demand, particularly influenced by weather conditions in India and Southeast Asia [7] - New Energy Vehicle Business: The company is successfully advancing customer demand and project milestones, with products expanding from PEU to vehicle-mounted compressors and other systems [7] Strategic Initiatives - The company is focusing on AI power solutions, with a significant increase in R&D personnel and investment in new technologies [7] - The company aims to leverage its technological and business advantages to benefit from the expected surge in AI infrastructure demand [7] Profit Forecast and Valuation - The net profit forecasts for 2025-2027 have been revised downwards to 313.6 million yuan, 833.77 million yuan, and 1.533 billion yuan respectively, with corresponding P/E ratios of 133x, 50x, and 27x [7]

Investment Rating - The report maintains a "Buy" rating for Yiling Pharmaceutical (002603.SZ) [6] Core Views - The company's Q3 revenue has rebounded, indicating strong growth potential for the full year, particularly with expectations for performance during the flu season [2] - The company has significantly improved its profitability metrics, with gross margin increasing by 7.14 percentage points to 60.53% and net profit margin rising by 8.33 percentage points to 17.05% [2] - The company is a leader in innovative traditional Chinese medicine, benefiting from policy incentives for innovation [4] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while net profit attributable to shareholders increased by 80.33% to 1 billion yuan [1] - Q3 revenue showed a significant improvement, with a quarter-on-quarter increase attributed to the recovery of core product shipments following marketing reforms [2] Research and Development - The company has increased R&D investment, with R&D expenses reaching 544 million yuan, accounting for 9.27% of revenue, a year-on-year increase of 0.29 percentage points [3] - Several innovative drugs have been approved or are in various stages of clinical trials, indicating a robust pipeline for future growth [3] Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been adjusted upwards, with net profit estimates of 1.304 billion yuan for 2025, 1.551 billion yuan for 2026, and 1.779 billion yuan for 2027 [4] - The current price corresponds to a price-to-earnings ratio of 22 for 2025, 19 for 2026, and 16 for 2027, reflecting a favorable valuation [4]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 7.42 [1]. Core Views - The company reported a revenue of RMB 19.31 billion for the first three quarters, a year-on-year increase of 64%, and a net profit attributable to shareholders of RMB 760 million, up 40% year-on-year. Despite significant stock gains in Q3, inventory impairment offset these gains, primarily due to price adjustments on long-cycle projects, which also led to positive sales growth in Q3 [1][2]. - The company is expected to benefit from improved sales and performance recognition in 2025, alongside favorable real estate policies in key cities and ongoing urban renewal projects [1]. Summary by Sections Financial Performance - In Q3, the company achieved a net profit of RMB 160 million, a decrease of 77% year-on-year, mainly due to an inventory impairment of RMB 860 million that offset stock gains from investments in Guoxin Securities and Nanwei Medical, which saw price increases of 17% and 49%, respectively [2][3]. - Cumulatively, for the first three quarters, the company’s net profit grew significantly due to a 44% increase in completed real estate area and improved stock gains, totaling RMB 1.01 billion, an increase of RMB 350 million year-on-year [3]. Sales and Land Acquisition - The company’s sales amount for the first three quarters decreased by 8% to RMB 14.1 billion, but Q3 saw a 3% increase in sales amount and a 103% increase in sales area, attributed to inventory clearance and price adjustments [4]. - The company acquired two land parcels in Beijing for a total price of RMB 5.3 billion, with a land acquisition intensity of 38% and an equity ratio of 40%. A new acquisition in Changping District for RMB 2.8 billion further expands its land reserves [4]. Profit Forecast and Valuation - The profit forecast for the company remains at RMB 835 million, RMB 840 million, and RMB 857 million for 2025-2027, respectively. The estimated BPS for 2026 is RMB 11.42. The average P/B ratio for comparable companies is 0.74, while the company’s reasonable P/B is set at 0.65, maintaining the target price of RMB 7.42 [5].